Similarly, sodium-glucose co-transported 2 inhibitors (SGLT2) demonstrated efficacy in patients with cancer therapy-related cardiac dysfunction or heart failure by demonstrating decreased heart failure exacerbation and all-cause mortality [29]. The gene discussed is SLC5A2; the disease is heart failure.